Literature DB >> 14576139

Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid.

Robin A Howe1, Mandy Wootton, Alan R Noel, Karen E Bowker, Timothy R Walsh, Alasdair P MacGowan.   

Abstract

The susceptibilities of clinical vancomycin-intermediate Staphylococcus aureus (VISA), heterogeneous VISA, and laboratory-generated linezolid-resistant S. aureus strains to the new oxazolidinone AZD2563 were assessed by agar dilution MIC determination. All clinical strains were susceptible to linezolid, and the linezolid MICs for them were equal to or twofold higher than those of AZD2563. Cross-resistance with linezolid was seen in laboratory-generated mutants, and for these strains the MIC of AZD2563 was twofold higher than that of linezolid.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14576139      PMCID： PMC253812          DOI： 10.1128/AAC.47.11.3651-3652.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.

Authors:  Alan P Johnson; Marina Warner; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

2.  Linezolid resistance in clinical isolates of Staphylococcus aureus.

Authors:  Peter Wilson; J A Andrews; R Charlesworth; R Walesby; M Singer; D J Farrell; M Robbins
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

3.  Linezolid resistance in a clinical isolate of Staphylococcus aureus.

Authors:  S Tsiodras; H S Gold; G Sakoulas; G M Eliopoulos; C Wennersten; L Venkataraman; R C Moellering; M J Ferraro
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

4.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

5.  Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action.

Authors:  L Xiong; P Kloss; S Douthwaite; N M Andersen; S Swaney; D L Shinabarger; A S Mankin
Journal:  J Bacteriol       Date:  2000-10       Impact factor: 3.490

6.  In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.

Authors:  Tamara R Anderegg; Douglas J Biedenbach; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 7.  The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.

Authors:  Timothy R Walsh; Robin A Howe
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

8.  Staphylococcus aureus resistant to vancomycin--United States, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-05       Impact factor: 17.586
  8 in total
  3 in total

1.  Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis.

Authors:  Lorena Diaz; Pattarachai Kiratisin; Rodrigo E Mendes; Diana Panesso; Kavindra V Singh; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

2.  Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

Review 3.  Linezolid Resistance in Staphylococci.

Authors:  Stefania Stefani; Dafne Bongiorno; Gino Mongelli; Floriana Campanile
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.